- Conditions
- Advanced Hepatocellular Carcinoma, Refractory Hepatocellular Carcinoma, Biliary Tract Cancer
- Interventions
- Ligufalimab, Cadonilimab
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Dallas, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–87
of 87
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Endometrial Neoplasms, Head and Neck Neoplasms
- Interventions
- disitamab vedotin
- Drug
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 75
- States / cities
- Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 36 more
- Conditions
- Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms, Carcinoma, Non-Small-Cell Lung, HER2 Mutations Breast Neoplasms
- Interventions
- tucatinib, trastuzumab, fulvestrant
- Drug
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 217 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 76
- States / cities
- Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 47 more
- Conditions
- Advanced Solid Tumors
- Interventions
- ADCT-901
- Drug
- Lead sponsor
- ADC Therapeutics S.A.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 7
- States / cities
- Denver, Colorado • New Haven, Connecticut • Atlanta, Georgia + 4 more
- Conditions
- Hepatocellular Carcinoma, Liver Metastases, Cutaneous or Subcutaneous Lymph Node, Liver Tumors
- Interventions
- Talimogene Laherparepvec, Pembrolizumab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 9
- States / cities
- Scottsdale, Arizona • Santa Monica, California • Washington D.C., District of Columbia + 6 more
- Conditions
- Advanced Cancer, Lung Cancer, Head and Neck Cancer, Melanoma
- Interventions
- EOS-448, pembrolizumab, inupadenant, Dostarlimab, SOC chemotherapies
- Drug
- Lead sponsor
- iTeos Belgium SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 2
- States / cities
- San Diego, California • Bergen, New Jersey
- Conditions
- Melanoma, Carcinoma, Non-Small- Cell Lung
- Interventions
- SEA-CD40, pembrolizumab (KEYTRUDA®), pemetrexed, carboplatin
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 23
- States / cities
- Springdale, Arkansas • Los Angeles, California • San Francisco, California + 18 more
- Conditions
- Tumor, Solid, Gastrointestinal Cancer
- Interventions
- Ulixertinib, Hydroxychloroquine
- Drug
- Lead sponsor
- BioMed Valley Discoveries, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 9
- States / cities
- Tucson, Arizona • San Francisco, California • Fairway, Kansas + 6 more
- Conditions
- NSCLC, Metastatic Colorectal Carcinoma, Refractory Melanoma
- Interventions
- Pixatimod, Nivolumab, Cyclophosphamide (low dose)
- Drug
- Lead sponsor
- Diwakar Davar
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Advanced Solid Tumors, HER2 Mutation
- Interventions
- BAY2927088
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Duarte, California • Fort Myers, Florida + 8 more
- Conditions
- Neuroendocrine Tumor, Carcinoid Syndrome
- Interventions
- Enterade®, Functional Assessment of Chronic Illness Therapy for Patients with Diarrhea (version 4.0)
- Dietary Supplement · Other
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Solid Tumor, TNBC - Triple-Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer, Endometrial Cancer, Cutaneous Melanoma, Thyroid Cancer, Small-cell Lung Cancer, Prostate Cancer, SORT1+ Cancers
- Interventions
- TH1902
- Drug
- Lead sponsor
- Theratechnologies
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 5
- States / cities
- Detroit, Michigan • Grand Rapids, Michigan • Gettysburg, Pennsylvania + 2 more
- Conditions
- Solid Tumor, Adult, Solid Tumor Cancer
- Interventions
- DF6215, pembrolizumab, KEYTRUDA®
- Drug
- Lead sponsor
- Dragonfly Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Orange, California • San Diego, California + 5 more
- Conditions
- Lung Cancer
- Interventions
- Low-dose CT scan
- Device
- Lead sponsor
- Guardant Health, Inc.
- Industry
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 12,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 125
- States / cities
- Birmingham, Alabama • Fayetteville, Arkansas • Anaheim, California + 105 more
- Conditions
- Solid Tumor
- Interventions
- Debio 1143, Nivolumab
- Drug
- Lead sponsor
- Debiopharm International SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 11
- States / cities
- Gainesville, Florida • Tampa, Florida • Chicago, Illinois + 7 more